Nanox Imaging Ltd. (NASDAQ: NNOX), a leader in innovative medical imaging technology, announced that its subsidiary, Nanox AI Ltd., has entered into a sales reseller agreement with Vertec Scientific Ltd. for the commercialization of its Nanox.AI bone solution, HealthOST, in the United Kingdom. The agreement grants Vertec an exclusive license to market and resell HealthOST in the UK, subject to minimum annual license commitments, for an initial three-year term.
HealthOST is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes eligible routine CT scans to support clinicians in evaluating and assessing musculoskeletal disease of the spine, including osteoporosis. The clinical significance of this technology is underscored by the fact that osteoporosis often goes undetected until a fracture occurs, and this AI tool can help identify at-risk patients earlier by leveraging existing CT scans performed for other reasons.
The importance of this agreement is amplified by the recent recommendation from the National Institute for Health and Care Excellence (NICE). In November 2025, NICE recommended HealthOST and a previous version, HealthVCF, among five AI technologies for National Health Service (NHS) use as options to aid opportunistic detection of vertebral fragility fractures. This endorsement from NICE is a critical step toward integrating AI-driven screening into routine clinical practice within the UK's public healthcare system.
By securing an exclusive reseller partner in the UK, Nanox is positioning itself to capitalize on the NICE recommendation and facilitate the adoption of HealthOST across NHS trusts. The partnership with Vertec Scientific, a well-established supplier of medical equipment in the UK, is expected to accelerate market penetration and ensure that healthcare providers have access to this innovative technology. The agreement also includes minimum annual license commitments, which provide a predictable revenue stream for Nanox and demonstrate Vertec's confidence in the product's potential.
The broader implications of this development are significant. Osteoporosis is a major public health concern, particularly in aging populations, and early detection is crucial for preventing debilitating fractures. AI-based solutions like HealthOST offer a cost-effective and efficient method to screen large numbers of patients without additional radiation exposure or patient burden. By integrating such tools into routine CT scans, the NHS could improve patient outcomes while potentially reducing long-term healthcare costs associated with fracture management.
Nanox's strategic focus on preventive healthcare is evident in its comprehensive ecosystem, which includes the Nanox.ARC imaging system, AI-driven analytics, cloud-based solutions, and teleradiology services. The company aims to expand the reach of medical imaging beyond traditional hospital settings, making advanced diagnostics more accessible and efficient. This partnership with Vertec is a testament to that vision and represents a concrete step toward realizing the potential of AI in transforming musculoskeletal care.
As the healthcare landscape increasingly embraces digital health solutions, the collaboration between Nanox and Vertec could serve as a model for other regions. With the NICE endorsement and a dedicated reseller network, Nanox is well-positioned to establish HealthOST as a standard tool for osteoporosis screening in the UK, potentially paving the way for broader adoption across Europe and beyond. The success of this initiative could also spur further innovation in AI-based diagnostic tools, ultimately benefiting patients worldwide.
